IN2012DN01435A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01435A
IN2012DN01435A IN1435DEN2012A IN2012DN01435A IN 2012DN01435 A IN2012DN01435 A IN 2012DN01435A IN 1435DEN2012 A IN1435DEN2012 A IN 1435DEN2012A IN 2012DN01435 A IN2012DN01435 A IN 2012DN01435A
Authority
IN
India
Prior art keywords
coxibs
tramadol
nsaids
medicaments
pain
Prior art date
Application number
Other languages
English (en)
Inventor
Salaman Carlos Ramon Plata
Nicolas Tesson
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Priority claimed from PCT/EP2010/002385 external-priority patent/WO2011044962A1/en
Publication of IN2012DN01435A publication Critical patent/IN2012DN01435A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/58Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
IN1435DEN2012 2008-10-17 2010-04-19 IN2012DN01435A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20080384012 EP2177215A1 (en) 2008-10-17 2008-10-17 Co-crystals of tramadol and NSAIDs
PCT/EP2009/007451 WO2010043412A1 (en) 2008-10-17 2009-10-16 Co-crystals of tramadol and nsaids
PCT/EP2010/002385 WO2011044962A1 (en) 2009-10-16 2010-04-19 Co-crystals of tramadol and coxibs

Publications (1)

Publication Number Publication Date
IN2012DN01435A true IN2012DN01435A (pt) 2015-06-05

Family

ID=40673614

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1435DEN2012 IN2012DN01435A (pt) 2008-10-17 2010-04-19

Country Status (27)

Country Link
US (10) US20110257134A1 (pt)
EP (2) EP2177215A1 (pt)
JP (1) JP5645830B2 (pt)
KR (1) KR101679400B1 (pt)
CN (1) CN102186465B (pt)
AU (1) AU2009304235B2 (pt)
BR (1) BRPI0920358A2 (pt)
CA (1) CA2737754C (pt)
CY (1) CY1118374T1 (pt)
DK (1) DK2349238T3 (pt)
ES (1) ES2603962T3 (pt)
HR (1) HRP20161526T1 (pt)
HU (1) HUE030976T2 (pt)
IL (1) IL211785A (pt)
IN (1) IN2012DN01435A (pt)
LT (1) LT2349238T (pt)
MX (1) MX336318B (pt)
MY (1) MY156285A (pt)
NZ (1) NZ591873A (pt)
PL (1) PL2349238T3 (pt)
PT (1) PT2349238T (pt)
RU (1) RU2599717C2 (pt)
SI (1) SI2349238T1 (pt)
SM (1) SMT201600439B (pt)
UA (1) UA109534C2 (pt)
WO (1) WO2010043412A1 (pt)
ZA (1) ZA201102762B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2177215A1 (en) * 2008-10-17 2010-04-21 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of tramadol and NSAIDs
RU2547830C2 (ru) * 2009-10-16 2015-04-10 Лабораторьос Дель Др. Эстеве, С.А. Сокристаллы трамадола и коксибов
EP2392319A1 (en) 2010-06-04 2011-12-07 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical compositions of co-crystals of tramadol and coxibs
CN102970989A (zh) * 2010-07-12 2013-03-13 永信药品工业股份有限公司 曲马多的双氯芬酸盐
DE102010063609A1 (de) * 2010-12-20 2012-06-21 Awd.Pharma Gmbh & Co. Kg Neue Multikomponentenkristalle aus ([2-Amino-6-(4-fluoro-benzylamino)-pyridin-3yl)-carbamidsäureethylester und einer Arylpropionsäure
KR101888852B1 (ko) 2011-12-02 2018-09-21 삼성전자주식회사 휴대용 단말기에서 다이버시티 서비스를 제공하기 위한 장치 및 방법
GB201222287D0 (en) 2012-12-11 2013-01-23 Ct For Process Innovation Ltd Methods for making active crystalline materials
ITMI20130210A1 (it) * 2013-02-14 2014-08-15 Menarini Lab Composizioni farmaceutiche contenenti dexketoprofene e tramadolo
RU2542100C1 (ru) * 2013-12-24 2015-02-20 Федеральное государственное бюджетное учреждение науки Институт химии растворов им. Г.А. Крестова Российской Академии Наук (ИХС РАН) Сокристаллическая форма теофиллина с дифлунисалом или диклофенаком
WO2016116942A1 (en) 2015-01-20 2016-07-28 Anlon Chemical Research Organization Novel pharmaceutical compounds comprising ticagrelor with salts of aspirin
CN104592009B (zh) * 2015-02-09 2017-02-22 黑龙江大学 萘普生药物共晶及其制备方法
US9693949B1 (en) * 2015-12-22 2017-07-04 Revogenex Ireland Ltd Intravenous administration of tramadol
MX2016006464A (es) * 2016-05-18 2017-11-17 Laboratorios Liomont S A De C V Composicion farmaceutica de una combinacion de clorhidrato de tramadol-etoricoxib para el tratamiento del dolor.
MX2019010640A (es) * 2017-03-08 2019-11-28 Intercept Pharmaceuticals Inc Formas cristalinas de acido obeticolico.
WO2019122982A1 (en) 2017-12-21 2019-06-27 Grünenthal GmbH Pharmaceutical combination in a bilayer tablet form comprising ketorolac tromethamine and tramadol hydrochloride, and its use in pain treatment
MX2018013070A (es) 2017-12-29 2019-10-15 Gruenenthal Gmbh Combinación farmacéutica que comprende clorhidrato de tramadol de liberación extendida y etoricoxib de liberación inmediata, y su uso para el tratamiento del dolor.
US11510926B2 (en) 2018-05-31 2022-11-29 The Royal Institution For The Advancement Of Learning/Mcgill University Pharmaceutical salts/co-crystals of pentoxifylline, clonidine and linsidomine with caffeic, protocatechuic or alpha-lipoic acid an use thereof for treatment of pain
US20210317086A1 (en) * 2018-08-20 2021-10-14 Mylan Laboratories Limited Tramadol HBR-Celecoxib Co-Crystal
WO2020121326A1 (en) 2018-12-13 2020-06-18 Mylan Laboratories Limited Amorphous (rac)-tramadol.hcl-celecoxib (1:1)
MA55954A (fr) * 2019-05-14 2022-03-23 Esteve Pharmaceuticals Sa Utilisation de co-cristaux de tramadol et de célécoxib pour traiter la douleur tout en réduisant le risque d'abus de tramadol
EP4169903A1 (en) * 2021-10-25 2023-04-26 Dompe' Farmaceutici S.P.A. Co-crystals of nonsteroidal anti-inflammatory drugs, lysine and gabapentin, pharmaceutical compositions and their medical use
KR20240027436A (ko) * 2022-08-23 2024-03-04 대원제약주식회사 펠루비프로펜 및 트라마돌의 이온결합 화합물, 이를 포함하는 조성물, 및 이의 제조 방법

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3652589A (en) 1967-07-27 1972-03-28 Gruenenthal Chemie 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols
EP0566709B3 (en) 1991-09-06 2009-04-08 Ortho-McNeil-Janssen Pharmaceuticals, Inc. Composition comprising a tramadol compound and acetaminophen, and its use
US5516803A (en) 1991-10-30 1996-05-14 Mcneilab, Inc. Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
AU661723B2 (en) * 1991-10-30 1995-08-03 Mcneilab, Inc. Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
DE69432193T2 (de) 1993-11-30 2004-01-15 Searle & Co Substituierte Pyrazolyl-benzolsulfonamide und ihre Verwendung als CyclooxygenaseII Inhibitoren
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
UA57002C2 (uk) 1995-10-13 2003-06-16 Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування
ATE408607T1 (de) 1996-04-12 2008-10-15 Searle Llc Substituierte benzensulfonamid-derivate als wirkstoff-vorläufer von cox-2 inhibitoren
US5861419A (en) 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
CN1152863C (zh) 1996-07-18 2004-06-09 麦克弗罗斯特(加拿大)公司 作为环氧合酶-2选择性抑制剂的取代的吡啶类化合物及其组合物
CO4960662A1 (es) 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
RS49982B (sr) 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
JP2002538176A (ja) * 1999-03-01 2002-11-12 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド トラマドール物質および選択的cox−2阻害薬を含んで成る組成物
DE19927688A1 (de) 1999-06-17 2000-12-21 Gruenenthal Gmbh Mehrschichttablette zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac
DE10108122A1 (de) 2001-02-21 2002-10-02 Gruenenthal Gmbh Arzneimittel auf Basis von Tramadol
CN1473035B (zh) 2001-07-27 2012-07-18 安斯泰来制药有限公司 含有口腔内迅速崩解片剂用缓释微粒的组合物及其制造方法
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
NZ535500A (en) 2002-02-19 2006-09-29 Adcock Ingram Ltd Pharmaceutical combinations of COX-2 inhibitors i.e. meloxicam, opiates i.e. codeine and centrally acting cox inhibitors i.e. paracetamol
EP1537258B9 (en) 2002-07-17 2008-10-29 S.O.I.Tec Silicon on Insulator Technologies Method of fabricating substrates, in particular for optics, electronics or optoelectronics----------------------------------------
CN1245968C (zh) 2002-10-09 2006-03-22 新疆特丰药业股份有限公司 一种萘普生钠缓释片剂的制备方法
JP4469846B2 (ja) 2003-01-31 2010-06-02 エラン ファーマ インターナショナル,リミティド ナノ粒子状トピラメート製剤
CA2514733A1 (en) * 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
JP2007516259A (ja) 2003-12-09 2007-06-21 メッドクリスタルフォームズ、エルエルシー 活性剤との混合相共結晶の調製方法
US8216610B2 (en) * 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
DE102006056458A1 (de) * 2006-11-28 2008-05-29 Grünenthal GmbH Arzneimittelzubereitung von Tramadol und Acetaminophen
WO2008085674A1 (en) 2007-01-04 2008-07-17 Transform Pharmaceuticals, Inc. Pharmaceutical compositions comprising celecoxib co-crystals
US20080031950A1 (en) * 2007-04-27 2008-02-07 Nectid Inc. Novel anelgesic combination
EP2022778A1 (en) * 2007-08-07 2009-02-11 Laboratorios del Dr. Esteve S.A. A crystalline form of (R,R)-tramadol-(S)-naproxene salt
KR101698028B1 (ko) 2008-05-20 2017-01-26 노이로제스엑스, 인코포레이티드 수용성 아세트아미노펜 유사체
PL2326632T3 (pl) 2008-09-06 2017-10-31 Bionevia Pharmaceuticals Inc Nowy kokryształ choliny i epalrestatu
EP2177215A1 (en) * 2008-10-17 2010-04-21 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of tramadol and NSAIDs
RU2547830C2 (ru) * 2009-10-16 2015-04-10 Лабораторьос Дель Др. Эстеве, С.А. Сокристаллы трамадола и коксибов
EP2311446A1 (en) 2009-10-16 2011-04-20 Laboratorios Del. Dr. Esteve, S.A. Compositions comprising Tramadol and Celecoxib in the treatment of pain
MX2012003050A (es) 2009-10-16 2012-05-29 Esteve Labor Dr Co-cristales de tramadol y coxibs.
EP2568990A4 (en) * 2010-05-07 2013-10-09 Care Fusion 2200 Inc METHOD OF PRODUCING PLEURODESIS
EP2392319A1 (en) * 2010-06-04 2011-12-07 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical compositions of co-crystals of tramadol and coxibs
MA55954A (fr) * 2019-05-14 2022-03-23 Esteve Pharmaceuticals Sa Utilisation de co-cristaux de tramadol et de célécoxib pour traiter la douleur tout en réduisant le risque d'abus de tramadol

Also Published As

Publication number Publication date
US10548909B2 (en) 2020-02-04
SMT201600439B (it) 2017-01-10
US9012440B2 (en) 2015-04-21
MX2011003612A (es) 2011-05-10
CN102186465A (zh) 2011-09-14
CY1118374T1 (el) 2017-06-28
KR101679400B1 (ko) 2016-11-24
SI2349238T1 (sl) 2017-01-31
US10245276B2 (en) 2019-04-02
RU2011119608A (ru) 2012-11-27
US20150196504A1 (en) 2015-07-16
EP2349238A1 (en) 2011-08-03
ZA201102762B (en) 2011-12-28
PL2349238T3 (pl) 2017-06-30
US9393220B2 (en) 2016-07-19
PT2349238T (pt) 2016-11-24
US20140057879A1 (en) 2014-02-27
RU2599717C2 (ru) 2016-10-10
EP2349238B1 (en) 2016-08-24
CN102186465B (zh) 2015-09-16
KR20110069860A (ko) 2011-06-23
EP2177215A1 (en) 2010-04-21
LT2349238T (lt) 2016-12-27
HUE030976T2 (en) 2017-06-28
HRP20161526T1 (hr) 2016-12-16
US20200171055A1 (en) 2020-06-04
BRPI0920358A2 (pt) 2020-08-11
MX336318B (es) 2016-01-14
US20140350110A1 (en) 2014-11-27
AU2009304235B2 (en) 2015-05-07
US20170000806A1 (en) 2017-01-05
US10238668B2 (en) 2019-03-26
MY156285A (en) 2016-01-29
JP5645830B2 (ja) 2014-12-24
WO2010043412A1 (en) 2010-04-22
US8598152B2 (en) 2013-12-03
US20190231800A1 (en) 2019-08-01
US11478488B2 (en) 2022-10-25
IL211785A (en) 2016-07-31
ES2603962T3 (es) 2017-03-02
CA2737754A1 (en) 2010-04-22
JP2012505847A (ja) 2012-03-08
IL211785A0 (en) 2011-06-30
DK2349238T3 (en) 2016-12-12
US20170027965A1 (en) 2017-02-02
UA109534C2 (uk) 2015-09-10
US20120172398A1 (en) 2012-07-05
US20150196503A1 (en) 2015-07-16
US20110257134A1 (en) 2011-10-20
NZ591873A (en) 2012-12-21
AU2009304235A1 (en) 2010-04-22
CA2737754C (en) 2016-09-20

Similar Documents

Publication Publication Date Title
IN2012DN01435A (pt)
TN2012000515A1 (en) Pharmaceutical compositions of co-crystals of tramadol and coxibs
IN2012DN02805A (pt)
TN2015000278A1 (en) Autotaxin inhibitors
MY161088A (en) Agonists of gpr40
MX342643B (es) Formas de dosificacion farmaceutica que comprenden poli (e-caprolactona).
HK1148202A1 (en) Pharmaceutical solutions, process of preparation and therapeutic uses
MX337575B (es) Compuestos de sulfona y métodos para lafabricación y uso de éstos.
HK1140940A1 (en) Titration of tapentadol
HK1173380A1 (en) Co-crystals of tramadol and coxibs
EA017091B9 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
UA104988C2 (uk) Похідні піроніндолу та спосіб їх отримання
GB0620385D0 (en) Novel compounds
MY156302A (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ß-AMYLOID DISEASES AND SYNUCLEINOPATHIES
PH12014502623B1 (en) Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors
MY150931A (en) Substituted oxazolidinones and their use
MX2009008108A (es) Composicion farmaceutica que contiene una combinacion de tramadol y ketoprofeno.
TN2012000075A1 (en) Co-crystals of tramadol and coxibs
UA112981C2 (uk) Варіант людського gdnf
WO2010028130A3 (en) Antidepressant compounds
WO2010027189A3 (ko) 호모아이소플라베논 또는 이의 염의 신규한 용도
TN2010000431A1 (en) New formulations, tablets comprising such formulations, their use and process for their preparation
UA42862U (uk) ЗАСТОСУВАННЯ М'ЯКОЇ ЛІКАРСЬКОЇ ФОРМИ, ЯКА МІСТИТЬ АКТИВНУ РЕЧОВИНУ β-ФЕНІЛЕТИЛАМІД 2-ОКСИСУКЦИНАНІЛОВОЇ КИСЛОТИ, ДЛЯ ЛІКУВАННЯ ОПІКОВИХ УРАЖЕНЬ ШКІРИ
TN2011000617A1 (en) 17 - alkyl-17 -oxy-oestratrienes
EA200900174A1 (ru) Фармацевтическая композиция для лечения желудочных расстройств